87776-75-8

Usage

Uses

Used in Biochemical Research:
3-Chloro-4-(methylthio)phenylacetic acid is utilized as a biochemical research reagent, serving as a key component in various experimental setups and analyses. Its unique structure allows it to interact with biological systems, making it valuable for studying molecular mechanisms and pathways.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 3-Chloro-4-(methylthio)phenylacetic acid is employed as an intermediate in the synthesis of various drugs. Its chemical properties enable it to be a building block for creating new medicinal compounds, contributing to the development of novel treatments and therapies.
Used in Agrochemical Production:
3-Chloro-4-(methylthio)phenylacetic acid also finds application in the agrochemical sector, where it is used in the synthesis of pesticides and other agricultural chemicals. Its role in these products helps to improve crop protection and yield.
Used in Organic Chemistry:
3-Chloro-4-(methylthio)phenylacetic acid is a valuable asset in the field of organic chemistry, where it is used in the synthesis of complex organic molecules and the study of reaction mechanisms. Its versatility in forming different chemical bonds makes it a useful tool for organic chemists.
Used in Medicinal Chemistry:
3-Chloro-4-(methylthio)phenylacetic acid is applied in medicinal chemistry for the design and synthesis of potential drug candidates. Its structural features can be manipulated to create compounds with specific biological activities, aiding in the advancement of pharmaceutical research.
Used in Biotechnology:
In biotechnology, 3-Chloro-4-(methylthio)phenylacetic acid is used in the development of new biological products and processes. Its ability to interact with biological molecules makes it a candidate for applications such as enzyme inhibition, drug targeting, and the creation of biosensors.

InChI:InChI=1/C9H9ClO2S/c1-13-8-3-2-6(4-7(8)10)5-9(11)12/h2-4H,5H2,1H3,(H,11,12)

Upstream product

• 947701-14-6 3-chloro-4-methylthiophenylacetic thiomorpholide 
• 947701-13-5 3-chloro-4-methylthio-phenylacetonitrile 
• 17733-22-1 2-chlorothioanisole 
• 393165-02-1 (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid methyl ester 
• 300355-11-7 (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid ethyl ester 

Downstream Products

• 87776-71-4 C₁₆H₁₅⁽²⁾H₂ClO₃S₂ 
• 436141-65-0 (3-chloro-4-methylsulfanyl-phenyl)-acetic acid methyl ester 
• 588940-69-6 (3-chloro-4-methylsulfanyl-phenyl)-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl acetamide 
• 300355-14-0 (3-chloro-4-methylsulfanylphenyl)acetic acid ethyl ester 
• 1072429-71-0 2-(3-chloro-4-(methylthio)phenyl)propanoic acid 
• 345635-33-8 (E)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-acrylic acid 
• 300356-14-3 (R)-2-(3-chloro-4-(methylsulfonyl)phenyl)-3-cyclopentylpropanoic acid 
• 1265819-83-7 (3-Chloro-4-methanesulfonyl-phenyl)acetic acid 
• 1265819-87-1 (E)-2-(3-Chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-acrylic acid Sodium Salt 
• 1265819-90-6 (R)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionic acid, dicyclohexylamine salt 
• 1266162-63-3 (R)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionic acid acid sodium salt 
• 1265819-85-9 (E)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-acrylic acid dicyclohexylamine salt 
• 1265819-92-8 (S)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionic acid 
• 1265819-93-9 (S)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionic acid, dicyclohexylamine salt 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN SO2-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a S02-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients

Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies.

Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions

Vanilloid receptor ligand compounds corresponding to formula I: a process for producing such compounds, pharmaceutical compositions containing them, and the use of such compounds to treat pain and various other vanilloid receptor mediated conditions.

PROCESS FOR PREPARING 3, 4-DISUBSTITUTED PHENYLACETIC ACIDS AND NOVEL INTERMEDIATES

A process for preparing 3,4-disubstituted phenylacetic acids of the formula (I) in which X is fluorine, chlorine, bromine or iodine and R is C1-C4-alkylthio, C1-C4-alkylsulfonyl or C1-C4-al

5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS

The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.

Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Fused heteroaromatic glucokinase activators

Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes.